Prior radiotherapy is allowed if more than days have elapsed since the end of treatment Cohort A Dose Expansion (Ribociclib + PDR): Prior radiotherapy: \r\n* Participants may have received radiotherapy for palliative purposes but must have completed treatment >= days prior to first dose of study treatment and not be experiencing grade > treatment-related toxicities Pamolidomide: days Systemic antineoplastic therapy or radiotherapy within days before the first dose of any study drug Radiotherapy within days before randomization; seven days may be considered if to single area Radiotherapy within days before enrollment Radiotherapy within days prior to baseline. Radiotherapy administered less than days prior to the first dose of the IMP, or localized palliative radiotherapy administered less than days prior to the first dose of the IMP, or radiotherapy-induced toxicity of Grade or greater based on NCI-CTCAE v .. Radiotherapy within days before enrollment; if the involved field covered =< % of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy Radiotherapy or chemotherapy within the days prior to the first dose of BGB being administered (other than hydroxyurea) Radiotherapy within days before randomization. Radiotherapy within days before enrollment; radiotherapy is excluded during induction and consolidation while receiving MLN Prior radiotherapy =< days Systemic antineoplastic therapy or radiotherapy for other malignant conditions within days before the first dose of any study drug Systemic antineoplastic therapy or radiotherapy within days before the first dose of any study drug, except for hydroxyurea Has received prior approved radiotherapy within days of study therapy. Has received chemotherapy or radiotherapy within days of first dose of study medication No chemotherapy or radiotherapy within the past days Patients must not have had chemotherapy =< days or radiotherapy =< days prior to study treatment Patients who have had chemotherapy or radiotherapy within days of enrollment Systemic antineoplastic therapy or radiotherapy for other malignant conditions within days before the first dose of any study drug, except for hydroxyurea Radiotherapy within days before randomization; seven days may be considered if to single area Radiotherapy =< days prior to registration Patients must not have had chemotherapy or radiotherapy =< days prior to study registration Have received NO radiotherapy within days prior to receiving study drug Radiotherapy within days before enrollment Radiotherapy to any site for any reason within days prior to study entry Received radiotherapy ? days prior to the first dose of AP of study drug. Radiotherapy within days prior to initiation of study treatment Systemic antineoplastic therapy or radiotherapy for other malignant conditions within days before the first dose of any study drug, except for hydroxyurea Concurrent radiotherapy, radiotherapy within days of first GT dose, previous radiotherapy to the target lesion sites, or prior radiotherapy to > % of bone marrow The patient has not received stereotactic radiotherapy within days prior to initiation of study treatment or whole-brain radiotherapy within days prior to initiation of study treatment. Treatment with prior radiotherapy within days of initiating study drug; however, if the radiation portal covered =< % of the bone marrow reserve, the patient may be enrolled without respect to the end date of radiotherapy Radiotherapy to any site for any reason within days prior to treatment Radiotherapy within days prior to first IMP administration. Radiotherapy within days of study treatment The participant received radiotherapy within days prior to randomization. Radiotherapy within days of study treatment Radiotherapy within days of randomization Prior radiotherapy within days of screening. Localized radiation therapy to a single site within the last days is acceptable. Concurrent radiotherapy is not permitted. Radiotherapy within days prior to randomization except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture, which can then be completed within days prior to randomization. Subjects must have recovered from radiotherapy toxicities prior to randomization Radiotherapy less than or equal to (<=) days prior to Day Concurrent radiotherapy, radiotherapy within days of first trilaciclib (GT) dose Radiotherapy, at least days from last local site radiotherapy An interval of at least weeks between prior radiotherapy or at least days from prior chemotherapy, days from nitrosoureas and enrollment in this study; Radiotherapy within days prior to Cycle Day . However, if the radiation portal covered ? % of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy Radiotherapy within days of randomization Radiotherapy within days prior to first dose. Radiotherapy within days prior to day of protocol therapy Whole brain radiation within days or other radiotherapy within days prior to first administration of study drug after crossing over Prior surgery or radiotherapy within days of therapy. The participant received radiotherapy within days prior to randomization. Radiotherapy within days before the first dose of study drug. Participants may or may not have received adjuvant radiotherapy, but must be at least days after last dose radiotherapy, with no more than grade residual toxicity at the time of screening No radiotherapy within days prior to cycle day ; however, if the radiation portal covered =< % of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy Radiotherapy within days of study treatment; patient must have recovered from acute effects of radiotherapy to baseline. Prior radiotherapy less than days prior to enrollment, except for WHO Grade glioma (radiotherapy is not permitted within months prior to enrollment) and ATC (radiotherapy is not permitted within days prior to enrollment). Treatment-related AEs must have resolved prior to enrollment. Patients who have had chemotherapy within days ( days for nitrosoureas or mitomycin C), radiotherapy within days, biological therapy within days, hormonal therapy within days, and investigational therapy within days prior to enrollment Radiotherapy within days before randomization. Radiotherapy to any site for any reason =< days prior to randomization Radiotherapy within days prior to cycle day ; however, if the radiation portal covered =< % of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy E . Less than days elapsed from prior treatment with estramustine, radiotherapy or surgery to the time of randomization. Participants on biphosphonates prior to study entry. Has had radiotherapy within days of randomization. Participants who received radiotherapy > days prior to randomization must have completely recovered from any radiotherapy-related AEs/toxicities Prior treatment with extended-field radiotherapy within days prior to enrollment or prior treatment with extended-field radiotherapy for evaluating tumor lesions within days prior to enrollment. Radiotherapy within the last days; Radiotherapy within days prior to first dose of study treatment Prior radiotherapy =< days, or if subjects have not recovered from radiotherapy Has received radiotherapy within the days prior to randomization, with the exception of palliative radiotherapy to focal lesions for pain or other symptom control Chemotherapy or radiotherapy within days prior to first dose of protocol therapy Radiotherapy within days prior to Baseline. Radiotherapy or chemotherapy ending within days of study enrollment Radiotherapy to any site for any reason within days prior to randomization, except for palliative radiotherapy to bone lesions within days prior to randomization Radiotherapy within days prior to first dose. Less than days elapsed from prior treatment with immunotherapy, radiotherapy, or surgery to the time of randomization. Radiotherapy within days before the first dose of study drug. Radiotherapy within days and abdominal/ pelvic radiotherapy within days prior to Day of Cycle , except palliative radiotherapy to bone lesions within days prior to Day of Cycle Radiotherapy within days before the first dose of study treatment. Radiotherapy within days preceding the first dose of study treatment Previous radiotherapy for the treatment of unresectable, locally advanced/recurrent or metastatic breast cancer is not allowed if:\r\n* The last fraction of radiotherapy has been administered within days of first on-study thormbokinetic study\r\n* The patient has not recovered from any resulting acute toxicity (to grade =< ) prior to first on-study thormbokinetic study Systemic antineoplastic therapy or radiotherapy within days before the first dose of study drug, except for hydroxyurea Patients should not have received radiotherapy within days prior to the first dose of orteronel Treatment with prior radiotherapy within days prior to first dose of study treatment; however, if the radiation portal covered ? % of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy. Radiotherapy within days of study treatment Radiotherapy to multiple sites or immunotherapy within days of initiation of study drug treatment (localized radiotherapy to a single site at least days before start is permissible) Radiotherapy to multiple sites or immunotherapy/antibody therapy within days prior to randomization; localized radiotherapy to a single site within days prior to randomization Radiotherapy within days and abdominal/pelvic radiotherapy within days prior to Day of Cycle Radiotherapy within days of first study treatment with the exception of a single fraction of radiation administered for palliation of symptoms Participants may or may not have received adjuvant radiotherapy, but must be at least days after last dose radiotherapy, with no more than grade residual toxicity at the time of screening